Your browser doesn't support javascript.
loading
A Large Case-Control Study Performed in Spanish Population Suggests That RECQL5 Is the Only RECQ Helicase Involved in Breast Cancer Susceptibility.
Marchena-Perea, Erik Michel; Salazar-Hidalgo, Milton Eduardo; Gómez-Sanz, Alicia; Arranz-Ledo, Mónica; Barroso, Alicia; Fernández, Victoria; Tejera-Pérez, Hugo; Pita, Guillermo; Núñez-Torres, Rocío; Pombo, Luz; Morales-Chamorro, Rafael; Cano-Cano, Juana María; Soriano, Maria Del Carmen; Garre, Pilar; Durán, Mercedes; Currás-Freixes, María; de la Hoya, Miguel; Osorio, Ana.
Afiliação
  • Marchena-Perea EM; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Salazar-Hidalgo ME; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Gómez-Sanz A; Molecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
  • Arranz-Ledo M; Cancer Genetics Group, Unidad de Excelencia Instituto de Biología y Genética Molecular, Universidad de Valladolid-Consejo Superior de Investigaciones Científicas (IBGM, UVa-CSIC), 47003 Valladolid, Spain.
  • Barroso A; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Fernández V; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Tejera-Pérez H; Human Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Pita G; Human Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Núñez-Torres R; Human Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Pombo L; Medical Oncology Section, Universitary Hospital Complex of Albacete, 02006 Albacete, Spain.
  • Morales-Chamorro R; Medical Oncology Section, Hospitalary Compex La Mancha Centro, 13600 Alcázar de San Juan, Spain.
  • Cano-Cano JM; Medical Oncology Service, Universitary General Hospital of Ciudad Real, 13005 Ciudad Real, Spain.
  • Soriano MDC; Oncology Service, Virgen de la Luz Hospital, 16002 Cuenca, Spain.
  • Garre P; Molecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
  • Durán M; Cancer Genetics Group, Unidad de Excelencia Instituto de Biología y Genética Molecular, Universidad de Valladolid-Consejo Superior de Investigaciones Científicas (IBGM, UVa-CSIC), 47003 Valladolid, Spain.
  • Currás-Freixes M; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • de la Hoya M; Molecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
  • Osorio A; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Cancers (Basel) ; 14(19)2022 Sep 28.
Article em En | MEDLINE | ID: mdl-36230663
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha